Multiple Sclerosis Mouse Models – Cuprizone-induced demyelination
mouse model
Test the efficacy of your remyelinating or neuroprotective compound, leveraging the gold standard cuprizone-induced demyelination mouse model of Multiple Sclerosis
Cuprizone-induced demyelination mouse model key characteristics
Cuprizone-induced demyelination mouse model is a gold standard mouse model for evaluating efficacy of novel therapeutics for multiple sclerosis focusing primarily oligodendrocyte precursor cells. Wild-type C57BL/6J mice fed a cuprizone-supplemented diet develop progressive demyelination of the corpus callosum and associated white and grey matter structures through selective oligodendrocyte apoptosis driven by copper chelation. Critically, since oligodendrocyte precursor cells are resistant to cuprizone toxicity, remyelination commences following cuprizone withdrawal, creating a defined, controllable window for evaluating remyelination-promoting therapies.
InnoSer performs preclinical efficacy studies in both acute (6-week) and chronic (12-week) cuprizone paradigms, each addressing distinct aspects of demyelination pathophysiology in diseases such as Multiple sclerosis and suited to different therapeutic hypotheses and dosing requirements. Importantly, the acute demyelination and remyelination model (6-week cuprizone diet followed by normal diet) captures oligodendrocyte loss, corpus callosum demyelination, and subsequent spontaneous OPC-driven remyelination within a relatively short disease and efficacy dosing window, enabling you to obtain quick insights into your compound’s efficacy. On the other hand, the chronic demyelination model (12-week cuprizone diet) enables longer dosing paradigms.
✓ InnoSer offers preclinical efficacy studies using the acute (6-week) and chronic (12-week) cuprizone paradigms
✓ Clemastine is available as positive control to benchmark the efficacy of your novel compounds
✓ Visually evoked potentials (VEP) available as a translationally relevant functional readout
✓ Histopathology (e.g., MBP, Caspr) used as endpoint structural readout to quantify degree of remyelination and paranodal junction integrity in the corpus callosum
As a preclinical immunology CRO, InnoSer offers well-established and clinically relevant multiple sclerosis mouse models, complemented with standardized study protocols to ensure consistency and reproducibility of your results. In addition, InnoSer offers preclinical research services using the lysolecithin-induced mouse model of multiple sclerosis and EAE mouse model. While both cuprizone-induced mouse model and lyolecithin mouse models enable you to test efficacy of compounds directed at remylienaiton, the EAE mouse model allows you to focus on the inflammatory component of Multiple sclerosis. However, as all models have their unique characteristics, we recommend discussing your study setup in close collaboration with our experts.
Align your dosing strategy with the biology
The cuprizone model offers flexible study designs spanning disease prevention, symptomatic intervention, and remyelination therapies. Depending on your therapeutic mechanism and development objectives, compound administration can be initiated at different stages of pathology progression.
InnoSer’s neuroscience team will help you match your compound’s mechanism to the right intervention window, model design, and endpoint panel — so your first in vivo study generates data that actually informs your next decision.
| Study type | Recommended dosing window | Typical applications |
|---|---|---|
| Preventive studies | Before cuprizone exposure or during the first week of cuprizone feeding. | Evaluate compounds targeting oligodendrocyte stress, apoptosis, metabolic dysfunction, or early neuroinflammatory processes before extensive demyelination develops. |
| Symptomatic studies | Weeks 2–6 of cuprizone exposure. | Assess therapeutic efficacy after pathology is established, including effects on neuroinflammation, demyelination, axonal damage, and disease progression. |
| Remyelination studies | Following cuprizone withdrawal (acute model) or during recovery from chronic cuprizone exposure. | Evaluate compounds that promote oligodendrocyte regeneration, remyelination, and functional recovery following established demyelinating lesions. |
Cuprizone-induced mouse model validation datasets
Functional demyelination was assessed at the end of the 6-week cuprizone exposure period using Visual Evoked Potential (VEP) recordings, evaluating both latency (conduction of action potentials) and amplitude (indicating axonal injury or persistent demyelination).
(A) VEP latency was significantly prolonged in cuprizone-treated mice compared with untreated controls, indicating impaired signal conduction through the visual pathway as a consequence of demyelination (**p < 0.0001 vs. baseline; Two-way ANOVA with Dunnett’s multiple comparisons test; N = 10).
(B) VEP amplitude was higher at week 6 as compared to baseline but remained the same between cuprizone-treated and control animals, demonstrating no axonal loss (Two-way ANOVA with Dunnett’s multiple comparisons test; N = 10). Data are represented as mean ± SD
Functional demyelination was assessed at the end of the 12-week cuprizone exposure period using visual evoked potentials (VEPs), evaluating both latency (conduction of action potentials) and amplitude (axonal integrity).
(A) VEP latency was significantly prolonged in cuprizone-treated mice compared with untreated controls, indicating impaired signal conduction through the visual pathway (****p < 0.0001 vs. baseline; Two-way ANOVA with Dunnett’s multiple comparisons test; N = 5-32).
(B) VEP amplitude remained comparable between cuprizone-treated and control animals, demonstrating no axonal loss (Two-way ANOVA with Dunnett’s multiple comparisons test; N = 6-8). Data are represented as mean ± SD.
Key readouts in the Cuprizone mouse model:
The People Behind Your Research
Sofie Carmans, PhD
Principal Scientist Neurology
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
Hasselt University/BIOMED
As part of a joint initiative to advance preclinical MS research, InnoSer works together with researchers from BIOMED, who focus on immunological mechanisms, myelination, and damage processes in the brain during MS.
Frequently Asked Questions
What reference compounds can InnoSer work with in the cuprizone mouse model?
For preclinical efficacy studies in the cuprizone mouse model, InnoSer recommends selecting Clemastine as the reference benchmark for your new compound. Clemastine fumarate is a well-established, approved antihistamine drug. Its mechanism of action is antagonism of the M1 muscarinic acetylcholine receptor (M1R) on oligodendrocyte precursor cells (OPCs), which removes a negative regulatory signal for OPC differentiation into mature myelinating oligodendrocytes.
Furthermore, across the scientific literature, Clemastine fumarate has a well-characterised dose-response relationship in the cuprizone model, enhancing remyelination (Li et al., 2015), and has been tested in clinical trials in Multiple Sclerosis patients (Green et al., 2017). This provides you with a direct, translational benchmark that helps link your efficacy datasets to the published clinical literature.
How does the cuprizone mouse model differ from EAE mouse model of multiple sclerosis that InnoSer works with?
The key distinction between the cuprizone-induced mouse model and the EAE mouse model lies in the immune mechanism driving demyelination.
The cuprizone model induces oligodendrocyte apoptosis through metabolic toxicity, with demyelination occurring in the absence of significant peripheral adaptive immune infiltration, in contrast to the EAE model, T and B lymphocytes do not play a central role in the development of demyelinating pathology. Therefore, the cuprizone-induced mouse model is more suitable for compounds targeting oligodendrocyte biology, oligodendrocyte precursor cell (OPC) differentiation and repair pathways, without the confounding influence of immune‑mediated processes.
In the EAE mouse model, by contrast, the disease pathology of multiple sclerosis, is driven by T and B cell-mediated neuroinflammation. Therefore, for compounds primarily targeting peripheral T cell or B cell-mediated immunity, the EAE model is more appropriate.
Contact our team to discuss which model best fits your compound’s mechanism of action.
What is the value of adding VEP as a readout in my preclinical efficacy study in the cuprizone model?
Visually evoked potentials (VEPs) measure the brain’s electrical response to visual stimuli, providing a direct functional assessment of myelin integrity along the visual pathway. In clinical practice, this method is used to assess the functional integrity of the visual pathways, particularly in the context of demyelinating disease, such as Multiple sclerosis.
In preclinical mouse models, functional assessment using VEPs offers a sensitive and translational measure of myelin integrity; demyelination slows the conduction of action potentials, which is reflected as a prolongation of VEP latency, while a reduction in amplitude may indicate axonal injury or persistent demyelination (Leocani et al., 2018). In accordance, subsequent remyelination restores the signal conduction velocity.
VEPs therefore serve as a functional biomarker of myelin repair and complement structural readouts such as myelin basic protein (MBP) or the paranode marker Contactin-Associated Protein (Caspr) quantification and histological analysis (Caverzasi et al., 2023; Green et al., 2017). Together, the cuprizone model and VEP readout constitute a powerful experimental framework for evaluating the remyelinating efficacy of pharmacological agents.
Discover Other Relevant Mouse Models
Discover InnoSer’s Latest Research
![Translational Neuroscience: Comprehensive longitudinal profiling of the Tau[P301S] female vs male mice](https://www.innoserlaboratories.com/wp-content/uploads/2026/06/Female-TauP301S-mice-show-early-spontaneous-hyperactivity-in-automated-home-cages-PhenoTyperTM-229375_1080x323.png)
Translational Neuroscience: Comprehensive longitudinal profiling of the Tau[P301S] female vs male mice
In this month’s newsletter, we highlight and build upon our knowledge working with the Tau[P301S] mouse model (originally described by Allen et al., 2002), and its applicability in preclinical research.Female and male...
Clinically relevant biomarker panels for comprehensive efficacy studies in Alzheimer’s Disease mouse models
InnoSer's validated Alzheimer's disease (AD) mouse models are equipped with translationally relevant biomarker readout panels — spanning amyloid-beta (Aβ) species, phosphorylated Tau isoforms, and the early, sensitive hallmark of neurodegeneration, neurofilament light...
![Proven Compound Susceptible Tau[P301S] Mouse Model for Preclinical Proof of Concept](https://www.innoserlaboratories.com/wp-content/uploads/2026/03/Proven-Compound-susceptible-TauP301S-mouse-model-for-preclinical-proof-of-concept--1080x675.png)
Proven Compound Susceptible Tau[P301S] Mouse Model for Preclinical Proof of Concept
The Tau[P301S] mouse remains one of the most established in vivo models for evaluating therapeutics targeting tauopathies including Alzheimer's disease and frontotemporal dementia (FTD). Presented at AD/PD 2025 in Vienna, this poster provides comprehensive...
Home-Cage Behavior Discriminates Neurodegeneration Models from Healthy Aging Mice
Distinguishing pathological neurodegeneration from normal biological aging is a fundamental challenge in preclinical neuroscience. Presented at AD/PD 2023 in Gothenburg, this poster — developed in collaboration with Sylics and VU University Amsterdam — establishes a...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. InnoSer’s facilities in the Netherlands and Belgium have been AAALAC-accredited since 2016 and 2020, respectively. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com